Humana Inc. filings document formal disclosures for a public healthcare company with Humana insurance services and CenterWell healthcare services. Recent 8-K reports cover quarterly results, GAAP and non-GAAP earnings measures, Insurance segment benefit ratio commentary, Medicare Advantage membership assumptions, Regulation FD communications, and guidance updates.
Humana's SEC records also include proxy and annual-meeting materials covering director elections, auditor ratification, stockholder voting results, board composition, and director compensation program disclosures; board and executive transition disclosures; and capital-structure filings for registered debt offerings, including junior subordinated notes described through Form S-3 and prospectus-supplement materials.
Humana Inc. director Frank A. D'Amelio reported new and existing equity holdings in the company. On 01/02/2026, he acquired 766 restricted stock units, which represent a contingent right to receive Humana common stock under the company’s 2019 Amended & Restated Plan. These units, along with other deferred stock units, are generally payable in Humana common stock on a 1-for-1 basis after his resignation as a director.
The filing shows a total of 26,826 restricted stock units held directly after the reported transaction, plus additional deferred stock units from converting director cash fees (2,467 units) and reinvested dividends (318 units). It also notes 20,634 Humana common shares held indirectly in a 2024 Grantor Retained Annuity Trust for which he serves as sole trustee.
Humana Inc. director Jorge S. Mesquita reported receiving 766 restricted stock units of Humana common stock on 01/02/2026. These units represent a contingent right to receive one share of Humana common stock for each unit and are noted as exempt under Rule 16b-3(d)(1)&(3) pursuant to the company's 2019 Amended & Restated Plan.
Following this grant, a total of 4,127 Humana shares, including the 766 restricted stock units, are reported as beneficially owned indirectly through a revocable trust where Mesquita is the sole trustee.
Humana Inc. director Kurt J. Hilzinger reported routine equity compensation activity. On 12/31/2025, he acquired restricted stock units tied to his director compensation and dividend reinvestment, including 611 units from reinvested dividends and 357 units from electing to convert cash fees into stock units at a price of $258.8675 per unit. On 01/02/2026, he received an additional 766 restricted stock units as part of his annual director fee, all payable in Humana common stock on a 1-for-1 basis after his board service ends.
Following these transactions, Hilzinger directly beneficially owns 19,448 Humana common shares and holds multiple blocks of deferred restricted stock units, including 24,800 units in one plan-based award. These awards are reported as exempt under Rule 16b-3 and reflect compensation elections rather than open-market buying or selling.
Humana Inc. director Karen W. Katz reported changes in her equity holdings. The filing shows a disposition of 590 shares of Humana common stock. She also reported derivative holdings in the form of restricted stock units (RSUs).
On 01/02/2026, Katz acquired 766 RSUs, which are part of her annual director’s fee payable in stock units and deferred until her resignation, when they will convert into Humana common stock on a one-for-one basis. On 12/31/2025, she acquired an additional 49 RSUs, related to dividend reinvestment on vested and deferred stock units at a price of $258.8675 per underlying share. Some director cash fees were also elected to be converted into deferred stock units, all payable in Humana common stock on a one-for-one basis upon her resignation.
Humana Inc. director Gordon Smith reported changes in his equity holdings. A Form 4 filing shows he disposed of 765 shares of Humana common stock and received additional equity-based awards tied to his director compensation.
The filing reports 766 restricted stock units from his annual director fee, which are deferred and will convert into Humana common stock on a 1-for-1 basis when he leaves the board. It also shows 122 stock units from electing to convert his cash director fees into stock units and 10 additional stock units from the reinvestment of dividends on previously vested and deferred units. All of these awards are structured as deferred stock units payable in Humana common stock, consistent with the company’s director compensation and deferral plan.
Humana Inc. director Raquel C. Bono reported equity awards and deferrals. The filing shows she acquired 766 restricted stock units as part of her annual director fee, which she elected to receive in stock units rather than cash. These units are deferred until she resigns from the board, at which time they will be settled in Humana common shares on a one-for-one basis under the company’s 2019 Amended & Restated Plan.
She also reported 34 additional stock units from dividend payments that were reinvested on already vested and deferred stock units. These dividend units are likewise deferred until she leaves board service and will then be paid in Humana common stock on a one-for-one basis.
Humana Inc. reported an insider equity transaction by its Chief Human Resources Officer, Michelle A. O'Hara. On 01/01/2026, she acquired 2,353 shares of Humana common stock through a transaction coded "M," at an exercise price of $0, reflecting the vesting or exercise of previously granted equity awards.
On the same date, she disposed of 1,093 shares, coded "F," at a price of $258.8675 per share, to cover tax liabilities related to shares vesting on that date, with no value received in return. After these transactions, she beneficially owned 9,541 shares of Humana common stock, which includes 7,512 restricted stock units that each represent a contingent right to receive one share under the company's 2019 Amended & Restated Plan.
Humana Inc. reported insider share transactions by its Chief Financial Officer, Celeste Mellet, dated 12/15/2025. She acquired 2,128 shares of Humana common stock at a price of $0, and 1,222 shares were disposed of at $270.155 per share to pay tax liabilities on vesting shares, with no value received in return.
Following these transactions, Mellet beneficially owned 28,454 Humana shares directly. This total includes 27,548 restricted stock units, each representing a contingent right to receive one share of Humana common stock under the Company's 2019 Amended & Restated Plan.
Humana Inc. Chief Information Officer Japan Mehta reported equity compensation activity in Humana common stock. On 12/15/2025, 1,194 shares were acquired at a reported price of $0, and 470 shares were disposed of at $270.155 to satisfy tax liability related to shares vesting on that date, with no value received in return.
After these transactions, Mehta beneficially owned 8,158 Humana shares directly. This total includes 7,434 restricted stock units that represent a contingent right to receive one share of Humana common stock each under the company’s 2019 Amended & Restated Plan. The report was signed on 12/17/2025.
Humana Inc. disclosed an insider stock transaction by its President, Enterprise Growth, David Dintenfass. On 12/15/2025 he exercised stock options for 2,032 shares of Humana common stock at an exercise price of $0 under the company’s 2019 Amended & Restated Stock Incentive Plan.
On the same date, 918 shares were disposed of at $270.155 per share to cover tax liabilities on vested restricted stock units, leaving 15,316 shares of common stock held directly, including 11,202 restricted stock units that each represent a right to receive one share. He also continues to hold stock options covering 51,389 shares at an exercise price of $367.21 per share, expiring on 02/21/2031 and vesting in three annual installments from 02/21/2025 through 02/21/2027.